Given that CD133 expression was associated with less DNA repair but enhanced inflammation and immune response, we hypothesized that CD133-high ER+/HER2− BC may be vulnerable to cellular insult and respond better to chemotherapy. This evidence concerns the gene PROM1 and breast cancer.